カテゴリ： 世界, 医療/バイオ, Market Monitor Global

神経変性疾患の遺伝子治療のグローバル市場展望 2023年-2029年：遺伝子置換療法、遺伝子サイレンシング療法、遺伝子編集療法、酵素置換療法

■ 英語タイトル：Gene Therapy for Neurodegenerative Diseases Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12350）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12350
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：66
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[神経変性疾患の遺伝子治療のグローバル市場展望 2023年-2029年：遺伝子置換療法、遺伝子サイレンシング療法、遺伝子編集療法、酵素置換療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の神経変性疾患の遺伝子治療市場規模と予測を収録しています。・世界の神経変性疾患の遺伝子治療市場：売上、2018年-2023年、2024年-2029年
・世界の神経変性疾患の遺伝子治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の神経変性疾患の遺伝子治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「遺伝子置換療法」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

神経変性疾患の遺伝子治療のグローバル主要企業は、Voyager Therapeutics、 Uniqure N.V.、 Axovant Gene Therapies、 Novartis Ag、 Amicus Therapeutics、 Regenxbio Inc.、 Sarepta Therapeutics、 Gensight Biologics、 Krystal Biotech、 Avexisなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、神経変性疾患の遺伝子治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の神経変性疾患の遺伝子治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の神経変性疾患の遺伝子治療市場：タイプ別市場シェア、2022年
・遺伝子置換療法、遺伝子サイレンシング療法、遺伝子編集療法、酵素置換療法

世界の神経変性疾患の遺伝子治療市場：用途別、2018年-2023年、2024年-2029年
世界の神経変性疾患の遺伝子治療市場：用途別市場シェア、2022年
・病院&診療所、研究機関、バイオテクノロジー企業、その他

世界の神経変性疾患の遺伝子治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の神経変性疾患の遺伝子治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における神経変性疾患の遺伝子治療のグローバル売上、2018年-2023年
・主要企業における神経変性疾患の遺伝子治療のグローバル売上シェア、2022年
・主要企業における神経変性疾患の遺伝子治療のグローバル販売量、2018年-2023年
・主要企業における神経変性疾患の遺伝子治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Voyager Therapeutics、 Uniqure N.V.、 Axovant Gene Therapies、 Novartis Ag、 Amicus Therapeutics、 Regenxbio Inc.、 Sarepta Therapeutics、 Gensight Biologics、 Krystal Biotech、 Avexis

*************************************************************

・調査・分析レポートの概要
神経変性疾患の遺伝子治療市場の定義
市場セグメント
世界の神経変性疾患の遺伝子治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の神経変性疾患の遺伝子治療市場規模
世界の神経変性疾患の遺伝子治療市場規模：2022年 VS 2029年
世界の神経変性疾患の遺伝子治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの神経変性疾患の遺伝子治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の神経変性疾患の遺伝子治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：遺伝子置換療法、遺伝子サイレンシング療法、遺伝子編集療法、酵素置換療法
神経変性疾患の遺伝子治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院&診療所、研究機関、バイオテクノロジー企業、その他
神経変性疾患の遺伝子治療の用途別グローバル売上・予測

・地域別市場分析
地域別神経変性疾患の遺伝子治療市場規模 2022年と2029年
地域別神経変性疾患の遺伝子治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Voyager Therapeutics、 Uniqure N.V.、 Axovant Gene Therapies、 Novartis Ag、 Amicus Therapeutics、 Regenxbio Inc.、 Sarepta Therapeutics、 Gensight Biologics、 Krystal Biotech、 Avexis
...

This research report provides a comprehensive analysis of the Gene Therapy for Neurodegenerative Diseases market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Gene Therapy for Neurodegenerative Diseases market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Gene Therapy for Neurodegenerative Diseases, challenges faced by the industry, and potential opportunities for market players.
The global Gene Therapy for Neurodegenerative Diseases market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Gene Therapy for Neurodegenerative Diseases market presents opportunities for various stakeholders, including Hospitals and Clinics, Research Institutions. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Gene Therapy for Neurodegenerative Diseases market. Additionally, the growing consumer demand present avenues for market expansion.
The global Gene Therapy for Neurodegenerative Diseases market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Gene Therapy for Neurodegenerative Diseases market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Gene Therapy for Neurodegenerative Diseases market.
Market Overview: The report provides a comprehensive overview of the Gene Therapy for Neurodegenerative Diseases market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Gene Replacement Therapy, Gene Silencing Therapy), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Gene Therapy for Neurodegenerative Diseases market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Gene Therapy for Neurodegenerative Diseases market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Gene Therapy for Neurodegenerative Diseases market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Gene Therapy for Neurodegenerative Diseases market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Gene Therapy for Neurodegenerative Diseases market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Gene Therapy for Neurodegenerative Diseases market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Gene Therapy for Neurodegenerative Diseases, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Gene Therapy for Neurodegenerative Diseases market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Gene Therapy for Neurodegenerative Diseases market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Gene Replacement Therapy
Gene Silencing Therapy
Gene Editing Therapy
Enzyme Replacement Therapy
Market segment by Application
Hospitals and Clinics
Research Institutions
Biotechnology Companies
Others
Global Gene Therapy for Neurodegenerative Diseases Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Voyager Therapeutics
Uniqure N.V.
Axovant Gene Therapies
Novartis Ag
Amicus Therapeutics
Regenxbio Inc.
Sarepta Therapeutics
Gensight Biologics
Krystal Biotech
Avexis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Neurodegenerative Diseases, market overview.
Chapter 2: Global Gene Therapy for Neurodegenerative Diseases market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Neurodegenerative Diseases company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Neurodegenerative Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Gene Therapy for Neurodegenerative Diseases Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Therapy for Neurodegenerative Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy for Neurodegenerative Diseases Overall Market Size
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size: 2022 VS 2029
2.2 Global Gene Therapy for Neurodegenerative Diseases Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene Therapy for Neurodegenerative Diseases Players in Global Market
3.2 Top Global Gene Therapy for Neurodegenerative Diseases Companies Ranked by Revenue
3.3 Global Gene Therapy for Neurodegenerative Diseases Revenue by Companies
3.4 Top 3 and Top 5 Gene Therapy for Neurodegenerative Diseases Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene Therapy for Neurodegenerative Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy for Neurodegenerative Diseases Players in Global Market
3.6.1 List of Global Tier 1 Gene Therapy for Neurodegenerative Diseases Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy for Neurodegenerative Diseases Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Gene Therapy for Neurodegenerative Diseases Market Size Markets, 2022 & 2029
4.1.2 Gene Replacement Therapy
4.1.3 Gene Silencing Therapy
4.1.4 Gene Editing Therapy
4.1.5 Enzyme Replacement Therapy
4.2 By Type – Global Gene Therapy for Neurodegenerative Diseases Revenue & Forecasts
4.2.1 By Type – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2023
4.2.2 By Type – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2024-2029
4.2.3 By Type – Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Gene Therapy for Neurodegenerative Diseases Market Size, 2022 & 2029
5.1.2 Hospitals and Clinics
5.1.3 Research Institutions
5.1.4 Biotechnology Companies
5.1.5 Others
5.2 By Application – Global Gene Therapy for Neurodegenerative Diseases Revenue & Forecasts
5.2.1 By Application – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2023
5.2.2 By Application – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2024-2029
5.2.3 By Application – Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Gene Therapy for Neurodegenerative Diseases Market Size, 2022 & 2029
6.2 By Region – Global Gene Therapy for Neurodegenerative Diseases Revenue & Forecasts
6.2.1 By Region – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2023
6.2.2 By Region – Global Gene Therapy for Neurodegenerative Diseases Revenue, 2024-2029
6.2.3 By Region – Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029
6.3.2 US Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.3.3 Canada Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.3.4 Mexico Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029
6.4.2 Germany Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.3 France Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.4 U.K. Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.5 Italy Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.6 Russia Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.7 Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.4.8 Benelux Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029
6.5.2 China Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.5.3 Japan Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.5.4 South Korea Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.5.5 Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.5.6 India Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029
6.6.2 Brazil Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.6.3 Argentina Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029
6.7.2 Turkey Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.7.3 Israel Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.7.4 Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
6.7.5 UAE Gene Therapy for Neurodegenerative Diseases Market Size, 2018-2029
7 Gene Therapy for Neurodegenerative Diseases Companies Profiles
7.1 Voyager Therapeutics
7.1.1 Voyager Therapeutics Company Summary
7.1.2 Voyager Therapeutics Business Overview
7.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.1.5 Voyager Therapeutics Key News & Latest Developments
7.2 Uniqure N.V.
7.2.1 Uniqure N.V. Company Summary
7.2.2 Uniqure N.V. Business Overview
7.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.2.5 Uniqure N.V. Key News & Latest Developments
7.3 Axovant Gene Therapies
7.3.1 Axovant Gene Therapies Company Summary
7.3.2 Axovant Gene Therapies Business Overview
7.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.3.5 Axovant Gene Therapies Key News & Latest Developments
7.4 Novartis Ag
7.4.1 Novartis Ag Company Summary
7.4.2 Novartis Ag Business Overview
7.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.4.5 Novartis Ag Key News & Latest Developments
7.5 Amicus Therapeutics
7.5.1 Amicus Therapeutics Company Summary
7.5.2 Amicus Therapeutics Business Overview
7.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.5.5 Amicus Therapeutics Key News & Latest Developments
7.6 Regenxbio Inc.
7.6.1 Regenxbio Inc. Company Summary
7.6.2 Regenxbio Inc. Business Overview
7.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.6.5 Regenxbio Inc. Key News & Latest Developments
7.7 Sarepta Therapeutics
7.7.1 Sarepta Therapeutics Company Summary
7.7.2 Sarepta Therapeutics Business Overview
7.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.7.5 Sarepta Therapeutics Key News & Latest Developments
7.8 Gensight Biologics
7.8.1 Gensight Biologics Company Summary
7.8.2 Gensight Biologics Business Overview
7.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.8.5 Gensight Biologics Key News & Latest Developments
7.9 Krystal Biotech
7.9.1 Krystal Biotech Company Summary
7.9.2 Krystal Biotech Business Overview
7.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.9.5 Krystal Biotech Key News & Latest Developments
7.10 Avexis
7.10.1 Avexis Company Summary
7.10.2 Avexis Business Overview
7.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Major Product Offerings
7.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue in Global Market (2018-2023)
7.10.5 Avexis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Gene Therapy for Neurodegenerative Diseases Market Opportunities & Trends in Global Market
Table 2. Gene Therapy for Neurodegenerative Diseases Market Drivers in Global Market
Table 3. Gene Therapy for Neurodegenerative Diseases Market Restraints in Global Market
Table 4. Key Players of Gene Therapy for Neurodegenerative Diseases in Global Market
Table 5. Top Gene Therapy for Neurodegenerative Diseases Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gene Therapy for Neurodegenerative Diseases Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gene Therapy for Neurodegenerative Diseases Product Type
Table 9. List of Global Tier 1 Gene Therapy for Neurodegenerative Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Therapy for Neurodegenerative Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Gene Therapy for Neurodegenerative Diseases Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gene Therapy for Neurodegenerative Diseases Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Gene Therapy for Neurodegenerative Diseases Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gene Therapy for Neurodegenerative Diseases Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2024-2029
Table 30. Voyager Therapeutics Company Summary
Table 31. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 32. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 33. Voyager Therapeutics Key News & Latest Developments
Table 34. Uniqure N.V. Company Summary
Table 35. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 36. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 37. Uniqure N.V. Key News & Latest Developments
Table 38. Axovant Gene Therapies Company Summary
Table 39. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 40. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 41. Axovant Gene Therapies Key News & Latest Developments
Table 42. Novartis Ag Company Summary
Table 43. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 44. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 45. Novartis Ag Key News & Latest Developments
Table 46. Amicus Therapeutics Company Summary
Table 47. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 48. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 49. Amicus Therapeutics Key News & Latest Developments
Table 50. Regenxbio Inc. Company Summary
Table 51. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 52. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 53. Regenxbio Inc. Key News & Latest Developments
Table 54. Sarepta Therapeutics Company Summary
Table 55. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 56. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 57. Sarepta Therapeutics Key News & Latest Developments
Table 58. Gensight Biologics Company Summary
Table 59. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 60. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 61. Gensight Biologics Key News & Latest Developments
Table 62. Krystal Biotech Company Summary
Table 63. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 64. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 65. Krystal Biotech Key News & Latest Developments
Table 66. Avexis Company Summary
Table 67. Avexis Gene Therapy for Neurodegenerative Diseases Product Offerings
Table 68. Avexis Gene Therapy for Neurodegenerative Diseases Revenue (US$, Mn) & (2018-2023)
Table 69. Avexis Key News & Latest Developments
List of Figures
Figure 1. Gene Therapy for Neurodegenerative Diseases Segment by Type in 2022
Figure 2. Gene Therapy for Neurodegenerative Diseases Segment by Application in 2022
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gene Therapy for Neurodegenerative Diseases Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Gene Therapy for Neurodegenerative Diseases Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
Figure 8. By Type - Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 9. By Application - Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 10. By Type - Global Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 12. By Application - Global Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 14. By Region - Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 15. By Country - North America Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 16. US Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 20. Germany Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 21. France Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 28. China Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 32. India Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 34. Brazil Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Gene Therapy for Neurodegenerative Diseases Revenue Market Share, 2018-2029
Figure 37. Turkey Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Gene Therapy for Neurodegenerative Diseases Revenue, (US$, Mn), 2018-2029
Figure 41. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Avexis Gene Therapy for Neurodegenerative Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ヒト遺伝子治療のグローバル市場展望 2023年-2029年：非ウイルスベクター、ウイルスベクター
  • 変形性関節症遺伝子治療のグローバル市場展望 2023年-2029年：滑膜注射、軟骨注射
  • がん遺伝子治療のグローバル市場（2022年-2029年）：腫瘍溶解性ウイルス療法、遺伝子誘導疫療法、遺伝子導入
  • 遺伝子治療薬送達チューブのグローバル市場展望 2023年-2029年：延長チューブタイプ、静脈カテーテルタイプ
  • エクソソーム治療技術のグローバル市場展望 2023年-2029年：医療、ドラッグデリバリー媒体、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12350 )"神経変性疾患の遺伝子治療のグローバル市場展望 2023年-2029年：遺伝子置換療法、遺伝子サイレンシング療法、遺伝子編集療法、酵素置換療法" (英文：Gene Therapy for Neurodegenerative Diseases Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。